 
Bio-IT World: Making Virtual Drug Development a Reality
GO >
MORE NEWS >
Download our Company
Fact Sheet
DOWNLOAD (PDF) >
Follow Stromedix on Twitter
GO >
|
|
Stromedix is led by a team of seasoned biotechnology industry veterans with deep experience in drug development, and the company has developed a strong network of world-class clinical and scientific advisers.
Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.
Our lead program, STX-100, has completed Phase 1 clinical testing.
The company is based in Cambridge, Massachusetts.
|
|
 
STX-100 is Stromedix's first clinical candidate and is being developed for the treatment of interstitial fibrosis and tubular atrophy in kidney transplant recipients and for idiopathic pulmonary fibrosis.
 |
Humanized monoclonal antibody to integrin αvβ6 |
|
Completed phase 1 clinical testing |
|
Provides localized, injury-specific inhibition of TGF-β activation
|
|
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease |
|
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer | |
